within Pharmacolibrary.Drugs.N_NervousSystem.N04A_AnticholinergicAgents.N04AB02_OrphenadrineChloride;

model OrphenadrineChloride
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.85,
    Cl = 1.633333333333333e-05,
    adminDuration = 600,
    adminMass = 100 / 1000000,
    adminCount = 1,
    Vd = 0.014,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.02333333333333333,
    Tlag = 10.200000000000001);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>OrphenadrineChloride</td></tr><tr><td>ATC code:</td><td>N04AB02</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>100</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>14</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.84</td><td>L/h/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Orphenadrine (chloride) is a centrally acting anticholinergic agent used primarily for the symptomatic treatment of Parkinson's disease and drug-induced extrapyramidal symptoms. It is also used as a muscle relaxant. Orphenadrine is still in use today, though newer alternatives exist.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after oral administration.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N04AB02 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end OrphenadrineChloride;
